FDA approves world's first RSV vaccine after 60 years of development
TL;DR Summary
The FDA has approved Arexvy, the world's first vaccine for respiratory syncytial virus (RSV), manufactured by GSK, which aims to prevent lower respiratory tract disease caused by RSV in people aged 60 and older. RSV can result in severe illness in older adults and young children, causing more than 60,000 hospitalizations and 6,000-plus deaths of US adults 65 and older each year. The vaccine reduced the risk of developing RSV-associated LRTD by 83% and lowered the risk of developing severe RSV-associated LRTD by 94%. The most commonly reported side effects of the vaccine are injection-site pain, fatigue, muscle pain, headache, and joint stiffness.
- World's first RSV vaccine approved by FDA — breakthrough 60 years in the making New York Post
- Boston doctor discusses FDA approval of first RSV vaccine WCVB Channel 5 Boston
- FDA approves first vaccine for RSV, a moment six decades in the making CNN
- FDA approves RSV vaccine for adults ages 60 and up NBC News
- FDA approves GSK's RSV vaccine for older adults, world's first shot against virus CNBC
Reading Insights
Total Reads
0
Unique Readers
17
Time Saved
3 min
vs 4 min read
Condensed
85%
686 → 103 words
Want the full story? Read the original article
Read on New York Post